Peptide Proof — Evidence-Based Peptide Intelligence. Independent analysis. No paywall.
The GLP-1 receptor agonist class — dominated by semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) — has reshaped modern medicine. But the peptide science behind these molecules points to applications far beyond metabolic disease.
The Expanding Therapeutic Horizon
Clinical trials are now exploring GLP-1 agonists for cardiovascular risk reduction, chronic kidney disease, liver fibrosis (NASH/MASH), neurodegenerative conditions including Alzheimer’s and Parkinson’s, and even addiction disorders. The SELECT trial showed semaglutide reduced major adverse cardiovascular events by twenty percent in overweight patients without diabetes — a landmark result that earned FDA approval for the cardiovascular indication in March 2024.
The Next Generation
Dual and triple agonists are the new frontier. Tirzepatide, also known as GIP/GLP-1 already demonstrated superior weight loss to semaglutide. Retatrutide (GIP/GLP-1/glucagon) from Eli Lilly showed up to 24.2 percent body weight reduction at 48 weeks in Phase 2 — unprecedented in obesity pharmacotherapy. Oral formulations and once-monthly injectables are also advancing rapidly through pipelines.
Manufacturing Challenges
The peptide synthesis supply chain is under unprecedented strain. Solid-phase peptide synthesis, also known as SPPS capacity is being expanded globally, with major CMO investments from WuXi STA, Bachem, PolyPeptide Group, and CordenPharma. The complexity of these 30–40 amino acid peptides — often requiring pseudoproline dipeptides and complex purification — keeps barriers to entry high.
What to Watch
The peptide therapeutics market is projected to reach seventy-five billion dollars by 2030, driven largely by metabolic disease. But the real story is the cascade of new indications being unlocked. Each new approval expands the total addressable market — and stretches an already tight manufacturing base.
[Natural sign-off — one sentence summary of why this matters.]
